Regeneron Pharmaceuticals Inc (WBO:REGN)
€ 757.4 -20.4 (-2.62%) Market Cap: 83.82 Bil Enterprise Value: 77.30 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 99/100

Regeneron Pharmaceuticals Inc COVID-19 Program Update Transcript

Sep 29, 2020 / 08:30PM GMT
Release Date Price: €489.5 (+1.02%)
Operator

Welcome to the Regeneron Pharmaceuticals COVID-19 Antibody Program Update Conference Call. My name is Gigi, and I will be your operator for today's call. (Operator Instructions)

Please note that this conference is being recorded. I will now turn the call over to Justin Holko, Vice President, Investor Relations. You may begin.

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Thank you, Gigi, and welcome to everybody listening to our webcast as we provide an update on the Regeneron COVID-19 Antibody Program. Joining me today are Dr. Len Schleifer, Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Co-Founder, President and Chief Scientific Officer; Dr. David Weinreich, Senior Vice President, Head of Clinical Development; Dr. Christos Kyratsous, Vice President, Infectious Diseases and Viral Vector Technologies; and Hala Mirza, Senior Vice President, Corporate Communications and Citizenship.

After our prepared remarks on the accompanying slides, which can be found on our website, we will open the call for Q&A from

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot